TABLE 4.
Persistence of DPP-4 Use by Index DPP-4 in MAPD and Commercial Populations
| Greater than 31-Day Gap by Index Medication | |||
|---|---|---|---|
| Frequency | Sitagliptin | Saxagliptin | Linagliptin |
| MAPD | n = 17,292 | n = 4,282 | n = 1,286 |
| > 31-day gap, n (% nonpersistent)a | 11,500 (66.50) | 2,772 (64.74) | 934 (72.63) |
| Adjusted OR of gap compared with linagliptin (95% CI)b | 0.751 (0.661-0.852) P = 0.007 |
0.693 (0.604-0.0796) P ≤ 0.001 |
Reference |
| Days to gap (SD)c | 218 days A (125) | 221 days A (128) | 209 days B (123) |
| Cox proportional hazard (95% CI)d | 0.88 (0.82-0.94) P < 0.001 |
0.85 (0.79-0.91) P < 0.001 |
Reference |
| Commercial | n = 2,368 | n = 643 | n = 218 |
| >31-day gap, n (% nonpersistent)a | 1,345 (56.8) | 396 (61.6) | 142 (65.1) |
| Adjusted OR of gap compared with linagliptin (95% CI)b | 0.71 (0.53-0.96) P = 0.004 |
0.86 (0.62-1.19) P = 0.860 |
Reference |
| Days to gap (SD)d | 237 days (129) | 232 days (127) | 230 days (122) |
| Cox proportional hazard (95% CI)d | 0.88 (0.74-1.02) P = 0.164 |
0.96 (0.79-1.16) P = 0.672 |
Reference |
aChi square: P < 0.001 MAPD, P = 0.01 commercial.
bLogistic regression controlling for age, gender, DCSI, and pre-index insulin use.
cANOVA means followed by different letters (A, B) are significantly different: P = 0.01 MAPD; P = 0.56 commercial.
dCox proportional hazard regression controlling for age, gender, DCSI, and pre-index insulin use.
ANOVA = analysis of variance; CI = confidence interval; DCSI = Diabetes Complications Severity Index; MAPD = Medicare Advantage Prescription Drug plan; OR = odds ratio; SD = standard deviation.